The Effect of Zinc Treatment with The Prostaglandin (PGF2α) and TNF-α Level in Dysmenorrhea Patients

Setia Nisa, Vaulinne Basyir, Afriwardi

Abstract—Background: The aim of the study determine the effect of zinc treatment with the prostaglandin (PGF2α) and TNF-α level in dysmenorrhea patients. Methods: The study was conducted using a quasi experimental with pre-post test group design. The study was conducted at Piala Sakiti School of Health Pariaman, West Sumatera Province, Indonesia from April-Mei 2018. The population in this study was teenagers with dysmenorrhea, sample size 22 people. Sampling technique with convenience sampling. This study used groups before treatment and after treatment of zinc treatment in the same group with a dose of 30 mg/ day for 3 days before pain. Test the normality of data by Shapiro-Wilk test and hypothesis test using paired t test. A two-tailed P-value of <0.05 was considered statistically significant. Results: The results showed that the mean of prostaglandin before treatment was 413.04 ± 11.52 pg/ ml after treatment 215.71 ± 8.13 pg/ ml and the mean of TNF-α level before treatment was 412.82 ± 10.90 ng/ L which after treatment 215.90 ± 10.77 ng/ L, the analysis used was to determine the effect of zinc treatment with PGF2α and TNF-α levels, using dependent T test, from this analysis the results were obtained prostaglandin levels (PGF2α) with P = 0.001 and TNF-α with p = 0.001 (p<0.05) Conclusion: The conclusion of this study confirmed there was an effect of zinc treatment with the prostaglandin (PGF2α) and TNF-α in dysmenorrhea patients.

Index Terms—zinc, prostaglandin, TNF-α

I. INTRODUCTION

Dysmenorrhea is pain in the pelvic area due to menstruation and the production of prostaglandin (PGF2α) and TNFα, often starting after experiencing the first menstruation (menarche). The prevalence of dysmenorrhea in each country has been carried out and shows various events. Australia shows a prevalence of 93% with moderate illness as much as 48% and strong illness as much as 21% [1]. Brazil is 86% with mild illness 25.5%, moderate illness 46.9% and strong illness 27.6% [2]. Dysmenorrhea prevalence in Ethiopia is 85% [3], Ghana as much as 74.4% with a prevalence of mild illness as much as 18.1%, moderate illness as much as 37.5%, and strong illness as much as 18.8% [4]. Switzerland is 86% where 12% are women with strong pain and 74.1% moderate pain [5].

Prevalence of dysmenorrhea in the southeast asian region is 85.8% of women with dysmenorrhea in Vietnam with 2% strong pain, 23.3% moderate to strong pain, 6.5% moderate pain, and 7.8% mild to moderate pain. The prevalence of dysmenorrhea in Indonesia is 64.25% consisting of 54.89% of primary dysmenorrhea and 9.36% of secondary dysmenorrhea. Primary dysmenorrhea is about 60-70% of adolescents experience it, three quarters of these adolescents experience mild to severe pain, another quarter experience severe pain [6]. The prevalence of dysmenorrhea in Indonesia is quite high.

Several factors in the occurrence of dysmenorrhea in it are an increase in the synthesis of prostaglandin (PGF2α) and cytokines (TNF α) which are important in addition to PGF2 α in the inflammatory process. Prevention that is commonly given to reduce menstrual pain is to provide both exogenous and endogenous antioxidants including Vitamin C, E, and A and micronutrient metal groups such as magnesium and zinc [7].

Zinc has an important role in regulating more than 300 metalloenzymes which function in physiological processes. Zinc deficiency is directly known to increase prostaglandin synthesis, inflammatory reactions, decrease sexual response, and protein damage [8]. Zinc has the ability to suppress the rate of synthesis of inflammatory factors, apoptosis and can be an antioxidant agent together with metalotionin. The inflammatory process in the endometrium can result in ischemic reactions in uterine tissue as a result of the myometrial contraction process [9].

The aim of the study determine the effect of zinc treatment with the prostaglandin (PGF2α) and TNF-α level in dysmenorrhea patients.

II. MATERIALS AND METHODS

A. Study Design and Research Sample

The study was conducted using a quasi experimental with pre-post test group design. The study was conducted at Piala Sakiti School of Health Pariaman, West Sumatera Province, Indonesia from April-Mei 2018. The population in this study was teenagers with dysmenorrhea, sample size 22 people. Sampling technique with convenience sampling. This study used groups before treatment and after treatment of zinc treatment in the same group with a dose of 30 mg/ day for 3 days before pain. Test the normality of data by Shapiro-Wilk test and hypothesis test using paired t test. A two-tailed P-value of <0.05 was considered statistically significant.

Setia Nisa, Master of Biomedical Program, Faculty of Medicine Universitas Andalas, Padang City, Indonesia
Vaulinne Basyir, Department of Obstetric and Gynaecology, Faculty of Medicine Universitas Andalas, Padang City, Indonesia
Afriwardi, Department of Physiology, Faculty of Medicine Universitas Andalas, Padang City, Indonesia.
The Effect of Zinc Treatment with The Prostaglandin (PGF2α) and TNF-α Level in Dysmenorrhea Patients

B. Operational Definitions

The variables of this study included independent variable is zinc treatment and dependent variable is prostaglandin (PGF2α) and TNF-α level in dysmenorrhea patients.

C. Data Collection Technique

This study was approved by the Ethical Committee of Medical Faculty, Universitas Andalas with registration number 283/KEP/FK/2018. The research tool in the form of a Numerical Rating Scale (NRS) to measure the scale of pain in which in this case, assessment of menstrual pain using a scale with the provisions of 0 (painless) and 10 (very painful) then the respondent points to the number of menstrual pain felt. In this study zinc was given a zinc trademark by Indoarma at a dose of 30 mg for three days before the date of menstruation. On the first day of menstruation, blood is taken for prostaglandin (PGF2α) and TNF-α examination.

D. Data Analysis

The quantitative variables were recorded as Mean±SD, median and percentage. Test the normality of data by Shapiro-Wilk test and hypothesis test using paired t test. A two-tailed P-value of <0.05 was considered statistically significant. A two-tailed P-value of <0.05 was considered statistically significant. Data were analyzed using the Stata version 14.2 (Stata Corporation).

III. RESULTS

Characteristics of respondents (Table 1).

Table 1: Characteristics of respondents

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Mean±SD (n=22)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of menarche (years)</td>
<td>13.00 ± 0.97</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>19.71 ± 0.41</td>
</tr>
</tbody>
</table>

Table 1 showed age of menarche 13.00 ± 0.97 years and body mass index 19.71 ± 0.41 kg/ m².

Table 2: The effect of zinc treatment with the prostaglandin level in dysmenorrhea patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Before Intervention (Mean ± SD)</th>
<th>After Intervention (Mean ± SD)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGF2 α (pg/ml)</td>
<td>413.04±11.52</td>
<td>215.71±8.13</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Table 2 showed the mean of PGF2 α before intervention is 413.04±11.52 pg/ml and after intervention 215.71±8.13 pg/ml. There was an effect of zinc treatment with the prostaglandin (PGF2α) level in dysmenorrhea patients (p<0.05).

Table 3: The effect of zinc treatment with the TNF-α level in dysmenorrhea patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Before Intervention (Mean ± SD)</th>
<th>After Intervention (Mean ± SD)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α (ng/L)</td>
<td>412.82±10.90</td>
<td>215.90±10.77</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Table 3 showed the mean of TNF-α before intervention is 412.82±10.90 ng/L and after intervention 215.90±10.77 ng/L. there was an effect of zinc treatment with the TNF-α level in dysmenorrhea patients.

IV. DISCUSSION

The result showed the mean of PGF2 α before intervention is 413.04±11.52 pg/ml and after intervention 215.71±8.13 pg/ml. There was an effect of zinc treatment with the prostaglandin (PGF2α) level in dysmenorrhea patients (p<0.05). The mean of TNF-α before intervention is 412.82±10.90 ng/L and after intervention 215.90±10.77 ng/L. There was an effect of zinc treatment with the TNF-α level in dysmenorrhea patients (p<0.05).

In this study, it was seen that Prostaglandin (PGF2-α) levels given zinc were lower than before zinc, because oral administration of zinc was known to have an inhibitory effect on prostaglandin synthesis enzymes because enzymes have an active side that can inhibit the rate of action of the enzyme. Zinc is also known to have anti-oxidant ability because it can bind free radicals so that the incidence of oxidative stress in cells can be reduced and inflammatory reactions do not occur. This physiological function improvement can directly reduce the degree of pain because zinc is able to provide a relaxing effect on the myometrial muscle or blood vessels.

The zinc dose used in this study was 30 mg daily based on a previous study [10]. The difference with this study is the difference in the treatment of zinc given to different people by comparing the mean level of prostaglandin (PGF2) given zinc before pain, with a placebo with a zinc dose of 30 mg given once a day, with a p value = 0.001 this shows the effect of giving zinc to prostaglandin levels so that with zinc treatment can reduce menstrual pain.

Zinc supplementation in primary dysmenorrhea has a significant value which is characterized by a p <0.05, a number of studies have shown that zinc can prevent primary dysmenorrhea. Some hypotheses about how zinc does it are by encouraging circulation to prevent the occurrence of ischemia and being able to reduce free radicals which are directly capable of suppressing or reducing inflammatory cytokines, one of which is TNF-α, this results in a decrease in pain [11].

Dysmenorrhea or menstrual pain can occur a very strong uterine contraction that can cause tissue ischemia so that there is expenditure of pain mediators such as prostaglandin. With zinc administration it is expected to improve circulation so that tissue ischemia can be prevented, zinc also regulates Cox-2, an enzyme involved in pain and inflammation, where zinc will reduce Cox-2 activity so that it can reduce prostaglandin synthesis and TNF- α level, zinc is also one of
the nutrients which can increase the conversion of essential fatty acids as anti-inflammatory for prostaglandins [8].

Based on the description above it can be concluded that zinc administration can reduce prostaglandin (PGF2-α) and TNF-α levels which are agents responsible for stimulating the occurrence of myometrial contractions which stimulate vascular contraception which results in pain, from the results of the study showed that the average decrease prostaglandin values (PGF2α) also followed a decrease in the average value of TNFα after being given zinc.

V. CONCLUSION

The conclusion of this study confirmed there was an effect of zinc treatment with the prostaglandin (PGF2α) and TNF-α in dysmenorrhea patients.

ACKNOWLEDGMENT

We would like to thank all respondents who participated in this study.

REFERENCES